日本化学療法学会雑誌第50巻第6号
|
|
|
- ああす かむら
- 7 years ago
- Views:
Transcription
1 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae S. pneumoniae 18 H. influenzae 4 S. pneumoniae H. influenzae 3 S. pneumoniae 18 S. pneumoniae 2 S. pneumoniae PSSP 2 PISP 4 PRSP 17 H. influenzae lactamase BLNAS 3 lactamase BLNAR 4 2 PSSP PISP AMPC PSSP AMPC PRSP PRSP 17 AMPC 2 4 PRSP 11 3 CDTR 1 AMPC 1 16 CDTR PRSP 1 PRSP 1 PRSP PRSP S. pneumoniae BLNAS 3 AMPC CDTR CDTR 1 BLNAS 1 BLNAS BLNAR 4 AMPC CDTR 2 BLNAR BLNAR H. influenzae 4 S. pneumoniae H. influenzae AMPC Key words: Streptococcus pneumoniae Haemophilus influenzae acute otitis media nasopharyngeal flora antibiotics Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae carrier forcus S. pneumoniae H. influenzae
2 S. pneumoniae H. influenzae amoxicillin AMPC cefditoren pivoxil CDTR I 1 S. pneumoniae H. influenzae 25 carrier forcus S. pneumoniae H. influenzae AMPC 50 mg kg day 3 14 CDTR 9mg kg day 3 14 CDTR 18 mg kg day First bacteriological examination first day antibiotics execution AMPC 50 mg/kg/day Second third day examination forth day antibiotics execution disappear AMPC 50 mg/kg/day remain CDTR 9 mg/kg/day Third seventh day examination eighth day antibiotics execution AMPC 50 mg/kg/day execution disappear CDTR 9 mg/kg/day execution remain CDTR 18 mg/kg/day Forth eleventh day examination twelfth day antibiotics not execution AMPC 50 mg/kg/day execution CDTR 9 mg/kg/day execution CDTR 18 mg/kg/day Fifth fourteenth day examination execution execution execution AMPC: amoxicillin, CDTR: cefditoren-pivoxil Fig. 1 Schedule of bacteriological examination and antibiotic treatment.
3 Fig. 1 2 PCR PCR S. pneumoniae H. influenzae S. pneumoniae H. influenzae polymerase chain reaction PCR 2 Ubukata S. pneumoniae lyta PBP pbp 1 a pbp 2 b pbp 2 x rrna ermam efflux mefe H. influenzae H. influenzae P6 PBP pbp 3 17 II Table 1 25 S. pneumoniae 18 H. influenzae 4 S. pneumoniae H. influenzae 3 S. pneumoniae 18 2 S. pneumoniae S. pneumoniae PSSP 2 2 PISP 4 4 PRSP H. influenzae lactamase BLNAS 3 3 lactamase BLNAR S. pneumoniae H. influenzae Table 1 PSSP 2 AMPC PRSP PRSP CDTR CDTR PSSP PISP 4 3 AMPC PISP 4 PSSP PISP PRSP BLNAS BLNAR PRSP 17 AMPC 2 4 PRSP PRSP PSSP PRSP CDTR 1 AMPC 1 16 CDTR 1 PRSP PRSP AMPC 1 PRSP CDTR PRSP PRSP S. pneumoniae 23 9 S. pneumoniae PRSP BLNAS 3 AMPC CDTR CDTR AMPC CDTR CDTR 1 1 BLNAR 4 AMPC CDTR 2 AMPC CDTR BLNAR H. influenzae Table 1 S. pneumoniae 13 S. pneumoniae 5 1 PSSP PRSP 4 PRSP PRSP
4 Table 1 1 Patient s profil and carriage of Streptococcus pneumoniae and Haemophilus influenzae before and after treatment by amoxicillin and cefditoren pivoxil Case Age Gender Day care Clinical result First M antibiotics germ variation germ volume 1 13 boy good AMPC pbp 1a2b2x,ermAM PRSP 2 BLNAS boy good AMPC pbp 2 x PISP M 1 BLNAS boy good AMPC pbp 3 BLNAR boy poor AMPC pbp 1a2b2x,mefE PRSP boy good AMPC pbp 2 x PISP M boy good AMPC pbp 1a2b2x PRSP boy good AMPC pbp 1a2b2x,ermAM PRSP boy good AMPC pbp 1a2b2x,mefE PRSP girl good AMPC pbp 3 BLNAR girl poor AMPC pbp 1a2b2x,mefE PRSP 2 pbp 2 x, ermam PISP M girl poor AMPC pbp 1a2b2x PRSP girl good AMPC pbp 3 BLNAR girl poor AMPC pbp 1a2b2x,mefE PRSP girl poor AMPC mefe PRSP 2 BLNAS girl good AMPC pbp 1a2b2x PRSP girl good AMPC pbp 1a2b2x,mefE PRSP girl poor AMPC PSSP girl good AMPC pbp 2 x PISP 3 pbp 1a2b2x,mefE PRSP girl good AMPC pbp 1a2b2x,mefE PRSP girl good AMPC pbp 1a2b2x PRSP girl poor AMPC pbp 1a2b2x,mefE PRSP girl good AMPC pbp 3 BLNAR girl good AMPC pbp 1a2b2x,mefE PRSP girl good AMPC pbp 1a2b2x,ermAM PRSP girl poor AMPC pbp 1a2b2x PRSP 3 In clinical result good: recovery case from acute otitis media at the last examination, poor: otitis prone case at the last examination In antibiotics AMPC: amoxicillin In germ PSSP: penicillin susceptible S. pneumoniae, PISP: penicillin intermediate resistant S. pneumoniae, PRSP: penicillin resistant S. pneumoniae, BLNAS: β lactamase negative ampicillin susceptible H. influenzae, BLNAR: β lactamase netative ampicillin resistant H. influenzae
5 Table 1 2 Patient s profil and carriage of Streptococcus pneumoniae and Haemophilus influenzae before and after treatment by amoxicillin and cefditoren pivoxil Case Second Third antibiotics germ variation germ volume antibiotics germ variation germ volume 1 CDTR disappear CDTR disappear BLNAS 1 disappear 2 AMPC disappear AMPC none disappear none 3 AMPC AMPC disappear none 4 CDTR pbp 1a2b2x,mefE PRSP 2 CDTR pbp 1a2b2x,mefE PRSP 2 5 AMPC disappear AMPC none 6 CDTR pbp 1a2b2x,mefE PRSP 2 CDTR pbp 1a2b2x,mefE PRSP 3 7 CDTR pbp 1a2b2x,ermAM PRSP 2 CDTR pbp 1a2b2x,ermAM PRSP 2 8 CDTR pbp 1a2b2x,mefE PRSP 2 CDTR pbp 1a2b2x,mefE PRSP 2 9 CDTR CDTR pbp 3 BLNAR 1 disappear 10 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 3 disappear none pbp 3, TEM BLNAR 3 disappear 11 CDTR pbp 1a2b2x PRSP 2 CDTR pbp 1a2b2x PRSP 2 BLNAS 1 12 CDTR CDTR pbp 3 BLNAR 1 disappear 13 CDTR pbp 1a2b2x PRSP 2 CDTR pbp 1a2b2x PRSP 2 pbp 3 BLNAR 1 pbp 3 BLNAR 1 14 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 2 BLNAS 2 BLNAS 1 15 CDTR pbp 1a2b2x PRSP 1 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x,mefE PRSP 2 disappear pbp 3 BLNAR 1 16 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 2 17 CDTR pbp 1a2b2x PRSP 3 CDTR pbp 1a2b2x PRSP 2 18 CDTR disappear CDTR none pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 19 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR disappear 20 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 3 BLNAR 3 21 CDTR pbp 1a2b2x,mefE,ermAM PRSP 3 CDTR pbp 1a2b2x,mefE,ermAM PRSP 22 AMPC AMPC disappear none 23 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 2 BLNAS 1 disappear 24 CDTR pbp 1a2b2x,ermAM PRSP 3 CDTR pbp 1a2b2x,ermAM PRSP 3 pbp 3 BLNAR 1 disappear 25 AMPC disappear AMPC none In antibiotics AMPC: amoxicillin, CDTR :cefditoren pivoxil 9 mg kg day CDTR :cefditoren pivoxil 18 mg kg day In germ PISP: penicillin intermediate resistant S. pneumoniae, PRSP: penicillin resistant S. pneumoniae, BLNAS: β lactamase negative ampicillin susceptible H. influenzae,blnar: β lactamase netative ampicillin resistant H. influenzae,none: not execution
6 Table 1 3 Patient s profil and carriage of Streptococcus pneumoniae and Haemophilus influenzae before and after treatment by amoxicillin and cefditoren pivoxil Case Forth Fifth Bacteriological antibiotics germ variation germ volume germ variation germ volume result 1 CDTR 2 AMPC 3 AMPC 4 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant 5 AMPC 6 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 1a2b2x,mefE PRSP 3 change 7 CDTR pbp 1a2b2x,ermAM PRSP 2 pbp 1a2b2x,ermAM PRSP 2 remnant 8 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant 9 CDTR 10 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 1a2b2x PRSP 3 change 11 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x PRSP 2 remnant disappear disappear disappearance 12 CDTR 13 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x PRSP 2 change disappear disappear disappearance 14 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 change disappear disappear disappearance 15 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x PRSP 2 remnant disappear disappear disappearance 16 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 3 remnant 17 CDTR pbp 1a2b2x PRSP 3 pbp 1a2b2x PRSP 3 change 18 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant 19 CDTR 20 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 1a2b2x,mefE PRSP 3 change pbp 3 BLNAR 1 pbp 3 BLNAR 1 appearance 21 CDTR pbp 1a2b2x,mefE,ermAM PRSP 3 pbp 1a2b2x,mefE,ermAM PRSP 3 change 22 AMPC 23 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant none BLNAS 1 appearance 24 CDTR pbp 1a2b2x,ermAM PRSP 3 pbp 1a2b2x,ermAM PRSP 3 remnant 25 AMPC none pbp 1a2b2x,mefE PRSP 3 change In antibiotics AMPC: amoxicillin, CDTR :cefditoren pivoxil 9 mg kg day CDTR :cefditoren pivoxil 18 mg kg day In germ PRSP: penicillin resistant S. pneumoniae, BLNAS: β lactamase negative ampicillin susceptible H. influenzae, BLNAR: β lactamase netative ampicillin resistant H. influenzae,none: not execution
7 8 H. influenzae 4 AMPC CDTR 1 BLNAR BLNAR CDTR S. pneumoniae H. influenzae 8 S. pneumoniae 7 S. pneumoniae 2 H. influenzae 2 PRSP S. pneumoniae 1 8 S. pneumoniae H. influenzae S. pneumoniae 2 S. pneumoniae PSSP AMPC PRSP S. pneumoniae H. influenzae BLNAS 1 BLNAR 2 3 Table 1 III S. pneumoniae S. pneumoniae 1967 Hansman 18 S. pneumoniae PRSP S. pneumoniae PRSP 3 9 H. influenzae lactamase lactamase H. influenzae BLNAR 2 17 S. pneumoniae PRSP PISP 3 9 H. influenzae 3 carrier forcus S. pneumoniae H. influenzae carrier forcus S. pneumoniae H. influenzae 1 AMPC CDTR CDTR S. pneumoniae S. pneumoniae PSSP PISP AMPC PSSP 2 PRSP PRSP PRSP S. pneumoniae PSSP PRSP PRSP PRSP
8 11 CDTR PSSP 2 4 PISP PRSP PRSP 2 PISP 1 Ghaffar 12 amoxicillin clavulanate CVA AMPC azithromycin AZM CVA AMPC PSSP PISP 75 PRSP 40 AZM AZM 2 3 Cohen CVA AMPC cefpodoxime proxetil CPDX 13 2 CVA AMPC ceftriaxone CTRX 14 CVA AMPC CPDX 13 CPDX 107 S. pneumoniae PSSP 58 PISP 27 PRSP 12 PSSP 15 PISP 27 PRSP 15 CVA AMPC 185 S. pneumoniae PSSP 59 PISP 25 PRSP 20 PSSP 9 PISP 15 PRSP PSSP PISP PRSP CTRX CVA AMPC 14 CTRX 247 S. pneumoniae PSSP 65 PISP 37 PRSP 4 PSSP 36 PISP 23 PRSP 40 CVA AMPC 250 S. pneumoniae PSSP 71 PISP 32 PRSP 48 PSSP 7 PISP 12 PRSP 22 CTRX 99 CVA AMPC 41 CTRX PSSP PISP PRSP CVA AMPC 41 7 PSSP PISP PRSP PSSP PISP PRSP S. pneumoniae PSSP PSSP PSSP PISP AMPC CDTR PISP H. influenzae 7 BLNAS AMPC CDTR CDTR 1 BLNAR AMPC CDTR 2 BLNAS BLNAR 1 11 CDTR CDTR Ghaffar 12 CVA AMPC AZM CVA AMPC lactamase H. influenzae 7 2 lactamase H. influenzae 10 8 AZM lactamase H. influenzae 9 2 lactamase H. influenzae 13 4 Cohen CVA AMPC CPDX 13 CVA AMPC CTRX 14 CVA AMPC CPDX 13 CVA AMPC lactamase H. influenzae 32 4 lactamase H. influenzae 43 4 CPDX lactamase
9 H. influenzae 26 4 lactamase H. influenzae 46 9 CVA AMPC CTRX 14 CVA AMPC lactamase H. influenzae 38 4 lactamase H. influenzae CTRX lactamase H. influenzae lactamase H. influenzae lactamase H. influenzae Ghaffar 12 Cohen lactamase BLNAS BLNAR lactamase H. influenzae BLNAR 2 PISP PRSP PSSP PISP 1 PRSP 11 PRSP PRSP S. pneumoniae 1 PSSP PRSP 4 PRSP PRSP PRSP PRSP H. influenzae 4 4 BLNAR AMPC CDTR CDTR 1 BLNAR CDTR 3 S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae Ghaffar 12 CVA AMPC PRSP AZM PRSP CVA AMPC AZM S. pneumoniae PRSP S. pneumoniae S. pneumoniae S. pneumoniae Ghaffar 12 S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae AMPC CDTR CDTR S. pneumoniae H. influenzae
10 1 : Haemophilus influenzae, Streptococcus pnemoniae Moraxella catarrhalis Jap J Antibiotics 50: : 16 S 2 : : 16: : 19: : 1 8: : 12: : JOHNS 13: : 101: : 47: : 82: : 49 S A : Ghaffar F, Stella L, Katz K, et al.: Effects of Amoxicillin Clavulanate or Azithromycin on nasopharyngeal Carriage of Streptococcus pneumoniae and Haemophilus influenzae in Children with Otitis Media. Clin Infect Dis 31: Cohen R Bingen E Varon E et al.: Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media in children. Pediatr Infect Dis J 16: Cohen R, Navel M, Grunberg J, et al.: One dose ceftriaxone vs. ten days of amoxicillin clavulanate therapy for acute otitis media: clinical efficancy and change in nasopharyngeal flora. Pediatr Infect Dis J 18: Ubukata K, Muraki T, Igarashi A, et al.: Identification of penicillin and Other Beta Lactam Resistance in Streptococcus pneumoniae using Polymerase Chain Reaction. J Infect Chemother 3: Ubukata K, Iwata S, Sunakawa K, et al.: In Vitro Activities of New Ketolide HMR 3647 and Other Macrolide Antibiotics Against Streptococcus pneumoniae Having ermam and Genes that Mediate macrolide. Antimicrob Agents Chemother in press 17 : BLNAR 9: Hansman D, Bullen M M: A resistant pneumococcus. Lancet 2: Jacobs M R Koornhof H J Robins Browne R M et al.: Emergence of multiply resistant pneumococci. NEngl J Med 299: : Jap J Antibiotics 34: : 92:
11 Changes in nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae from amoxicillin and cefditoren pivoxil therapy in children with acute otitis media Yoshihumi Uno UNO ENT Clinic Tomihara Okayama Japan Acute otitis media is one of the most common upper respiratory infection diseases in childhood. The most common organisms causing it are Streptococcus pneumoniae and Haemophilus influenzae In children the nasopharynx is the carrier focus for upper respiratory infection diseases such as acute otitis media, and S. pneumoniae and H. influenzae colonize the nasopharynx. We studied the changes in nasopharyngeal carriage of S. pneumoniae and H. influenzae before and after amoxicillin AMPC and cefditoren pivoxil CDTR therapy using a polymerase chain reaction to detect penicillin binding protein genes and macroride resistant genes with the following results: 1. In 25 cases 18 showed S. pneumoniae only 4 H. influenzae only and 3 detected cases. In the 18 having only S. pneumoniae 2 consisted of a different type of S. pneumoniae In 23 strains of S. pneumoniae 2 were penicillin susceptible S. pneumoniae PSSP 4 penicillin intermediate resistant S. pneumoniae PISP and 17 penicillin resistant S. pneumoniae PRSP In the 7 strains of H. influenzae 3 were lactamase negative ampicillin susceptible H. influenzae BLNAS and 4 lactamase negative ampicillin resistant H. influenzae BLNAR 2. All PSSP and PISP were removed from the nasopharynx with AMPC but in PSSP PRSP was detected in all cases after AMPC therapy. In the 17 strains of PRSP recognized initially 2 wereremoved from the nasopharynx with AMPC therapy 4changed to other strain types with AMPC therapy and of the 11 strains remaining 3 new strains appeared. With CDTR 9mg kg day therapy 2 strains were removed and 16 remained. With CDTR 18 mg kg day therapy 1 strainchanged to another type and 1newstrainappeared. Ultimately 17 strains remained but only 9 existed from the beginning. 3. All 3 BLNAS strains were removed from the nasopharynx with AMPC CDTR 9mg kg day and CDTR 18 mg kg day therapy. During these therapies however 3 BLNASappeared and only 1 strain ultimately remained in the nasopharynx. All 4 BLNAR strains were removed from the nasopharynx with AMPC with 3 new strains appearing and CDTR 18 mg kg day with 2 new strains appearing. One strain ultimately remained in the nasopharynx. All strains recognized initially were removed. 4. No relationship was seen between S. pneumoniae and H. influenzae remaining in the nasopharynx and results of acute otitis media therapy. But it was recognized the tendencies that in the good result cases the rate of the removal of the bacteria from the beginning were high and allofthem removed with AMPC and in the poor result cases the removal of the bacteria fromthebeginning were not high and bacteria from the beginning changed to the different bacteria which had different pattern of the resistant genes.
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%
207 ( 1 ) Cefditoren pivoxil G 2010 2 2 2006 3 Cefditoren pivoxil CDTR-PI MS 10% CDTR-PI 305 2,144 2,006 1,958 1.79% 36 2,006 26 (1.30%) CDTR-PI CDTR-PI (9 mg/kg/day) 1.5 2 (2.70%) 2 (1.92%) 93.5% 1,831
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab
June 2011 THE JAPANESE JOURNAL OF ANTIBIOTICS 64 23 179 ( 63 ) A b cefditoren pivoxil 5 amoxicillin 10 1,2) 1,3) 1) 1) 1) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 2011 4 8 2007 5 2009 4 A b GAS cefditoren pivoxil
172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae
Key words: penicillin insensitive and resistant pneumococcus Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae 小 児
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity CHEMOTHERAPY MAR. 1989 Mble 1. Allcrgy in parients nduced by penams VOL. 37 NO. 3 Table 2. Allergy in patients induced by
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
Table 1 Characteristics of the study participants in Imari municipal hospital
Key words: tuberculosis, booster phenomenon, two-step tuberculin test Table 1 Characteristics of the study participants in Imari municipal hospital Fig. 1 Frequency distributions of size of the first tuberculin
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
日本化学療法学会雑誌第55巻第S-1号
µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius
05_藤田先生_責
This report shows innovation of competency of our faculty of social welfare. The aim of evaluation competency is improvement in the Social welfare education effects, by understanding of studentʼs development
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
cover
日本耳鼻咽喉科感染症研究会会誌 (2012.05) 30 巻 1 号 :133~136. 急性中耳炎 急性鼻副鼻腔炎における抗菌薬の選択基準とバリアンス 林達哉 第 41 回日本耳鼻咽喉科感染症研究会 シンポジウム 上気道感染症治療の最前線 タイトル名 : 急性中耳炎 急性鼻副鼻腔炎における抗菌薬の選択基準とバリアンス 著者名 : 林達哉 ( はやしたつや ) 所属 : 旭川医科大学耳鼻咽喉科 頭頸部外科
〈企業特集：検査機器・試薬・技術の新たな展開〉新規マイコプラズマ抗原検査キット—プロラスト®Myco
New immunochromatographic assay kit for Mycoplasma pneumoniae infection 'PRORAST Myco' Shohei Ohshima, Yasushi Shimada, Atsuko Minagawa, Kazuyuki Sugiyama and Yumiko Hirayama Mycoplasma pneumoniae infection
Key words: Antibodies to Leptospira, Tokyo, Uveitis
Key words: Antibodies to Leptospira, Tokyo, Uveitis Fig. 1 Distribution of Antibody Titers in Age Decade Fig. 3 Distribution of Antibody Titers in each Strain Fig. 2 Correlation between Antibody Titers
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c
Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic clinic, Department of Ophthalmology, (Director: Prof
Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad
Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
日本化学療法学会雑誌第59巻第6号
P P Streptococcus pneumoniae S. pneumoniae Key words Streptococcus pneumoniae Fig. 1. Capsular swelling reaction of S. pneumoniae type 6B. Cells are stained dark blue using a methylene blue. Capsule is
.\...pwd
2007.2.1 200757 1,31-46 1) 629-0392 Department of Basic Oriental Medicine, Meiji University of Oriental Medicine Hiyoshi-cho, Nantan-shi, Kyoto, Japan 629-0392 57 1 2) 700 216 91 1 2 31 12 91 13 38 5 37
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
56 pp , 2005 * ******* *** ** CA CAMA
Title 成人知的障害者の加齢に伴う外観的変化に関する研究 : 知的障害者用外観的老化微候測定法を用いた検討 Author(s) 春日井, 宏彰 ; 菅野, 敦 ; 橋本, 創一 ; 桜井, 和典 ; 片瀬, Citation 東京学芸大学紀要. 第 1 部門, 教育科学, 56: 415-425 Issue Date 2005-03-00 URL http://hdl.handle.net/2309/2097
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
DISTRIBUTION OF NEUROPEPTIDES IN THE INFERIOR NASAL TURBINATE MUCOSA OF PATIENTS WITH ALLERGIC RHINITIS KAZUHIRO YAMAMOTO. M.D. Department of Otolaryngology, School of Medicine, Kitasato University, Sagamihara
感染症学雑誌第77巻第8号
1 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ
08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
日本化学療法学会雑誌第57巻第4号
Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
40B: 43-54 2010 43 2010 1 27 Satoshi Shimai 1 and Shigehiro Fujimoto 2 1 Center for Liberal Arts and Education, Minami-Kyushu University, Miyakonojo,
40B: 43-54 2010 2010 1 27 Satoshi Shimai 1 and Shigehiro Fujimoto 2 1 Center for Liberal Arts and Education, Minami-Kyushu University, Miyakonojo, Miyazaki 885-0035, Japan; 2 Miyakonojo Public Health Institute,
日本消化器外科学会雑誌第31巻第7号
Key words: obstructive jaundice, biliary drainage, bile refeeding, hepatectomy Fig. 1 Animal models a: experiment I b: experiment 2 silicon tube Fig. 2 Experimantal design Sham Ope J - l r bile duct Zweeks
CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized
国土技術政策総合研究所 研究資料
ISSN TECHNICAL NOTE of National Institute for Land and Infrastructure Management No256 September 2005 Experimental Study on Seismic Behavior of Seawalls for Controlled Waste Disposal Shingo KANO, Katsuya
Key words : influenza, nested-pcr, serotype
Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2
The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
日本化学療法学会雑誌第56巻第S-1号
Key words Streptococcus pneumoniae µ µ H F Cl H H N N H N F COOH O Fig.1. Sitafloxacinstructure. I γ S. pneumoniae Haemophilus influenzae Table1. Observationandtestschedule Observation/Tests Informedconsent
2 94
32 2008 pp. 93 106 1 Received October 30, 2008 The purpose of this study is to examine the effects of aerobics training class on weight loss for female students in HOKURIKU UNIVERSITY. Seventy four female
840 Geographical Review of Japan 73A-12 835-854 2000 The Mechanism of Household Reproduction in the Fishing Community on Oro Island Masakazu YAMAUCHI (Graduate Student, Tokyo University) This